Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Verrica Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Verrica Pharmaceuticals Inc’s stock price such as:

• Verrica Pharmaceuticals Inc’s current stock price and volume
• Why Verrica Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for VRCA from analysts
• VRCA’s stock price momentum as measured by its relative strength

About Verrica Pharmaceuticals Inc (VRCA)

Before we jump into Verrica Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Want to learn more about Verrica Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc’s Stock Price as of Market Close

As of June 10, 2024, 4:00 PM, CST, Verrica Pharmaceuticals Inc’s stock price was $8.56.

Verrica Pharmaceuticals Inc is up 4.65% from its previous closing price of $8.18.

During the last market session, Verrica Pharmaceuticals Inc’s stock traded between $8.16 and $8.93. Currently, there are 46.48 million shares of Verrica Pharmaceuticals Inc stock available for purchase.

Unfortunately, Verrica Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Verrica Pharmaceuticals Inc Stock Price History

Verrica Pharmaceuticals Inc’s (VRCA) price is currently up 0.59% so far this month.

During the month of June, Verrica Pharmaceuticals Inc’s stock price has reached a high of $9.36 and a low of $7.73.

Over the last year, Verrica Pharmaceuticals Inc has hit prices as high as $11.41 and as low as $2.86. Year to date, Verrica Pharmaceuticals Inc’s stock is up 211.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Verrica Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 07, 2024, there were 3 analysts who downgraded Verrica Pharmaceuticals Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Verrica Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Verrica Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Verrica Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Verrica Pharmaceuticals Inc (VRCA) by visiting AAII Stock Evaluator.

Relative Price Strength of Verrica Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 07, 2024, Verrica Pharmaceuticals Inc has a weighted four-quarter relative price strength of 16.07%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Verrica Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Verrica Pharmaceuticals Inc Stock Price: Bottom Line

As of June 10, 2024, Verrica Pharmaceuticals Inc’s stock price is $8.56, which is up 4.65% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Verrica Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.